Cover Image
市場調查報告書

胰臟癌診斷檢驗:醫療設備的開發平台評估

Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017

出版商 GlobalData 商品編碼 404484
出版日期 內容資訊 英文 205 Pages
訂單完成後即時交付
價格
Back to Top
胰臟癌診斷檢驗:醫療設備的開發平台評估 Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017
出版日期: 2017年09月01日 內容資訊: 英文 205 Pages
簡介

本報告提供全球胰臟癌診斷檢驗的各種設備的市場上,主要的開發中產品 (醫療設備) 與其臨床實驗的進展調查,產品特性比較分析 (臨床實驗的進展各階段) ,再加上主要企業簡介及代表性產品,近來的市場動靜 (資本交易、產業聯盟等) 的資訊彙整,為您概述為以下內容。

第1章 目錄

第2章 簡介

  • 胰臟癌診斷檢驗概要

第3章 現在臨床實驗中的產品

  • 開發中產品:各臨床實驗階段
  • 開發中產品:各領域
  • 開發中產品:各法規途徑
  • 開發中產品:各估計認證時期
  • 現在進行中的臨床實驗

第4章 胰臟癌診斷檢驗:各企業現在在臨床實驗中的開發中產品

  • 胰臟癌診斷檢驗的企業:各臨床實驗階段的開發中產品
  • 胰臟癌診斷檢驗:各臨床實驗階段的開發中產品

第5章 胰臟癌診斷檢驗的企業、產品概要

  • A&G Pharmaceutical Inc
    • 開發中產品及進行中的臨床實驗概要
  • Abcodia Ltd
  • Acobiom Company
  • Andraka Technologies, LLC
  • Applied Proteomics Inc
  • Asuragen, Inc.
  • Avant Diagnostics, Inc.
  • BioMarker Strategies LLC
  • Biouniversa srl
  • Cancer Research Technology Ltd
  • Cepheid
  • Cleveland Diagnostics Inc.
  • Clovis Oncology Inc
  • CompanDX Ltd.
  • Courtagen Life Sciences Inc
  • CS-Keys, Inc.
  • Di.V.A.L Toscana srl
  • Sciences Corp
  • German Cancer Research Center
  • GlycoZym
  • Health Discovery Corp
  • Hebrew University of Jerusalem
  • ImmunoCellular Therapeutics Ltd
  • Immunomedics Inc
  • Immunovia AB
  • Imperial College London
  • IV Diagnostics, Inc.
  • John Hopkins University
  • Leitat Technological Center
  • Matrix-Bio, Inc.
  • Mayo Clinic US
  • MDNA Life Sciences Inc
  • Merrimack Pharmaceuticals Inc
  • Metanomics Health GmbH
  • Milagen, Inc.
  • Miraculins Inc
  • Myriad Genetics Inc
  • NanoScale Corporation
  • NatiMab Therapeutics Srl
  • National Cheng-Kung University Hospital
  • Onconome, Inc. (Inactive)
  • OPKO Health Inc
  • Oxford Gene Technology Ltd
  • PeriRx LLC
  • Phenomenome Discoveries Inc
  • Precision Biologics Inc
  • Proplex Technologies Llc
  • Protagen AG
  • Proteome Sciences Plc
  • Queen Mary University of London
  • SDIX LLC
  • Sienna Cancer Diagnostics Ltd
  • SomaLogic Inc
  • Stanford University
  • Temple University Health System
  • Thomas Jefferson University
  • University of Illinois at Chicago
  • University of Pennsylvania
  • US Biomarkers Inc
  • Ventana Medical Systems Inc
  • Viomics Inc.
  • Vitatex Inc.
  • VolitionRX Ltd

第6章 胰臟癌診斷檢驗市場:目前的趨勢 (共64件)

第7章 附錄

圖表一覽

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

目錄
Product Code: GDME0419EPD

GlobalData's Medical Devices sector report, "Pancreatic Cancer Diagnostic Tests - Medical Devices Pipeline Assessment, 2017" provides an overview of Pancreatic Cancer Diagnostic Tests currently in pipeline stage.

The report provides comprehensive information on the pipeline products with comparative analysis of the products at various stages of development. The report reviews major players involved in the pipeline product development. It also provides information about clinical trials in progress, which includes trial phase, trial status, trial start and end dates, and, the number of trials for the key Pancreatic Cancer Diagnostic Tests pipeline products.

This report is prepared using data sourced from in-house databases, secondary and primary research by GlobalData's team of industry experts.

Note: Certain sections in the report may be removed or altered based on the availability and relevance of data in relation to the equipment type.

Scope

  • Extensive coverage of the Pancreatic Cancer Diagnostic Tests under development
  • The report reviews details of major pipeline products which includes, product description, licensing and collaboration details and other developmental activities
  • The report reviews the major players involved in the development of Pancreatic Cancer Diagnostic Tests and list all their pipeline projects
  • The coverage of pipeline products based on various stages of development ranging from Early Development to Approved / Issued stage
  • The report provides key clinical trial data of ongoing trials specific to pipeline products
  • Recent developments in the segment / industry

Reasons to buy

The report enables you to -

  • Formulate significant competitor information, analysis, and insights to improve R&D strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Identify and understand important and diverse types of Pancreatic Cancer Diagnostic Tests under development
  • Develop market-entry and market expansion strategies
  • Plan mergers and acquisitions effectively by identifying major players with the most promising pipeline
  • In-depth analysis of the product's current stage of development, territory and estimated launch date

Table of Contents

1 Table of Contents

1 Table of Contents 2

  • 1.1 List of Tables 7
  • 1.2 List of Figures 11

2 Introduction 12

  • 2.1 Pancreatic Cancer Diagnostic Tests Overview 12

3 Products under Development 13

  • 3.1 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 13
  • 3.2 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Territory 14
  • 3.3 Pancreatic Cancer - Pipeline Products by Regulatory Path 15
  • 3.4 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 16
  • 3.5 Pancreatic Cancer Diagnostic Tests - Ongoing Clinical Trials 17

4 Pancreatic Cancer Diagnostic Tests - Pipeline Products under Development by Companies 18

  • 4.1 Pancreatic Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 18
  • 4.2 Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 21

5 Pancreatic Cancer Diagnostic Tests Companies and Product Overview 24

  • 5.1 A&G Pharmaceutical Inc Company Overview 24
    • 5.1.1 A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 24
  • 5.2 Abcodia Ltd Company Overview 25
    • 5.2.1 Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
  • 5.3 Acobiom Company Overview 26
    • 5.3.1 Acobiom Pipeline Products & Ongoing Clinical Trials Overview 26
  • 5.4 Advanced Marker Discovery SL Company Overview 29
    • 5.4.1 Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 29
  • 5.5 Andraka Technologies, LLC Company Overview 30
    • 5.5.1 Andraka Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 30
  • 5.6 Applied Proteomics Inc Company Overview 31
    • 5.6.1 Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • 5.7 Avant Diagnostics, Inc. Company Overview 32
    • 5.7.1 Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
  • 5.8 BioMarker Strategies LLC Company Overview 33
    • 5.8.1 BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 33
  • 5.9 Bioprognos SL Company Overview 34
    • 5.9.1 Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 34
  • 5.10 Biouniversa srl Company Overview 35
    • 5.10.1 Biouniversa srl Pipeline Products & Ongoing Clinical Trials Overview 35
  • 5.11 Cancer Research Technology Ltd Company Overview 37
    • 5.11.1 Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
  • 5.12 Cepheid Company Overview 38
    • 5.12.1 Cepheid Pipeline Products & Ongoing Clinical Trials Overview 38
  • 5.13 Clovis Oncology Inc Company Overview 40
    • 5.13.1 Clovis Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • 5.14 CompanDX Ltd. Company Overview 41
    • 5.14.1 CompanDX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 41
  • 5.15 Courtagen Life Sciences Inc Company Overview 42
    • 5.15.1 Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • 5.16 CS-Keys, Inc. (Inactive) Company Overview 43
    • 5.16.1 CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 43
  • 5.17 Di.V.A.L Toscana srl Company Overview 44
    • 5.17.1 Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 44
  • 5.18 Exact Sciences Corp Company Overview 45
    • 5.18.1 Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 45
  • 5.19 Fred Hutchinson Cancer Research Center Company Overview 46
    • 5.19.1 Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 46
  • 5.20 German Cancer Research Center Company Overview 47
    • 5.20.1 German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 47
  • 5.21 GlycoZym Company Overview 48
    • 5.21.1 GlycoZym Pipeline Products & Ongoing Clinical Trials Overview 48
  • 5.22 Health Discovery Corp Company Overview 49
    • 5.22.1 Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 49
  • 5.23 Hebrew University of Jerusalem Company Overview 50
    • 5.23.1 Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 50
  • 5.24 ImmunoCellular Therapeutics Ltd Company Overview 51
    • 5.24.1 ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
  • 5.25 Immunomedics Inc Company Overview 52
    • 5.25.1 Immunomedics Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • 5.26 Immunovia AB Company Overview 53
    • 5.26.1 Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 53
  • 5.27 Imperial College London Company Overview 57
    • 5.27.1 Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 57
  • 5.28 IV Diagnostics, Inc. Company Overview 58
    • 5.28.1 IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 58
  • 5.29 John Hopkins University Company Overview 59
    • 5.29.1 John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 59
  • 5.30 Leitat Technological Center Company Overview 60
    • 5.30.1 Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 60
  • 5.31 Luminor Medical Technologies Inc Company Overview 62
    • 5.31.1 Luminor Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • 5.32 Matrix-Bio, Inc. Company Overview 63
    • 5.32.1 Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • 5.33 Mayo Clinic US Company Overview 64
    • 5.33.1 Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 64
  • 5.34 MDNA Life Sciences Inc Company Overview 65
    • 5.34.1 MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • 5.35 Merrimack Pharmaceuticals Inc Company Overview 66
    • 5.35.1 Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 66
  • 5.36 Metanomics Health GmbH Company Overview 67
    • 5.36.1 Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 67
  • 5.37 Milagen Inc Company Overview 68
    • 5.37.1 Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • 5.38 Myriad Genetics Inc Company Overview 69
    • 5.38.1 Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 69
  • 5.39 Nanocytomics LLC Company Overview 70
    • 5.39.1 Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 70
  • 5.40 NanoScale Corporation Company Overview 71
    • 5.40.1 NanoScale Corporation Pipeline Products & Ongoing Clinical Trials Overview 71
  • 5.41 NatiMab Therapeutics Srl Company Overview 72
    • 5.41.1 NatiMab Therapeutics Srl Pipeline Products & Ongoing Clinical Trials Overview 72
  • 5.42 National Cheng-Kung University Hospital Company Overview 73
    • 5.42.1 National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 73
  • 5.43 Oncomatryx Biopharma SL Company Overview 74
    • 5.43.1 Oncomatryx Biopharma SL Pipeline Products & Ongoing Clinical Trials Overview 74
  • 5.44 Onconome, Inc. (Inactive) Company Overview 76
    • 5.44.1 Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 76
  • 5.45 OPKO Health Inc Company Overview 78
    • 5.45.1 OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 78
  • 5.46 Oxford Gene Technology Ltd Company Overview 79
    • 5.46.1 Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 79
  • 5.47 PeriRx LLC Company Overview 80
    • 5.47.1 PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview 80
  • 5.48 Precision Biologics Inc Company Overview 81
    • 5.48.1 Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 81
  • 5.49 Proplex Technologies Llc Company Overview 83
    • 5.49.1 Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 83
  • 5.50 Protagen AG Company Overview 84
    • 5.50.1 Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 84
  • 5.51 Proteome Sciences Plc Company Overview 85
    • 5.51.1 Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 85
  • 5.52 Queen Mary University of London Company Overview 86
    • 5.52.1 Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 86
  • 5.53 Rutgers The State University of New Jersey Company Overview 87
    • 5.53.1 Rutgers The State University of New Jersey Pipeline Products & Ongoing Clinical Trials Overview 87
  • 5.54 SDIX LLC Company Overview 88
    • 5.54.1 SDIX LLC Pipeline Products & Ongoing Clinical Trials Overview 88
  • 5.55 Sienna Cancer Diagnostics Ltd Company Overview 89
    • 5.55.1 Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
  • 5.56 SomaLogic Inc Company Overview 90
    • 5.56.1 SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 90
  • 5.57 Stanford University Company Overview 91
    • 5.57.1 Stanford University Pipeline Products & Ongoing Clinical Trials Overview 91
  • 5.58 Temple University Health System Company Overview 92
    • 5.58.1 Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 92
  • 5.59 The Royal Marsden NHS Foundation Trust Company Overview 93
    • 5.59.1 The Royal Marsden NHS Foundation Trust Pipeline Products & Ongoing Clinical Trials Overview 93
  • 5.60 The University of North Carolina at Chapel Hill Company Overview 94
    • 5.60.1 The University of North Carolina at Chapel Hill Pipeline Products & Ongoing Clinical Trials Overview 94
  • 5.61 Thomas Jefferson University Company Overview 95
    • 5.61.1 Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview 95
  • 5.62 University of Illinois at Chicago Company Overview 96
    • 5.62.1 University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 96
  • 5.63 University of Pennsylvania Company Overview 97
    • 5.63.1 University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 97
  • 5.64 University of Texas MD Anderson Cancer Center Company Overview 98
    • 5.64.1 University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 98
  • 5.65 US Biomarkers Inc Company Overview 99
    • 5.65.1 US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 99
  • 5.66 Ventana Medical Systems Inc Company Overview 100
    • 5.66.1 Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 100
  • 5.67 Viomics Inc. Company Overview 101
    • 5.67.1 Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 101
  • 5.68 Vitatex Inc. Company Overview 102
    • 5.68.1 Vitatex Inc. Pipeline Products & Ongoing Clinical Trials Overview 102
  • 5.69 VolitionRX Ltd Company Overview 103
    • 5.69.1 VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 103

6 Pancreatic Cancer Diagnostic Tests - Recent Developments 106

  • 6.1 Aug 17, 2017: Victoria Laughman Named Executive Vice President of Sales for OPKO's BioReference Laboratories 106
  • 6.2 Aug 16, 2017: Immunomedics Announces Fiscal 2017 Results and Strategic Developments; Reiterates Guidance on BLA Submission Timeline 106
  • 6.3 Aug 14, 2017: Merrimack Augments Executive Team with Appointment of Jean Franchi as Chief Financial Officer 108
  • 6.4 Aug 14, 2017: ImmunoCellular Therapeutics Announces Second Quarter 2017 Financial Results 109
  • 6.5 Aug 09, 2017: Merrimack Reports Second Quarter 2017 Financial Results 110
  • 6.6 Aug 08, 2017: Halozyme Reports Second Quarter 2017 Results 111
  • 6.7 Aug 02, 2017: Clovis Oncology Announces Second Quarter 2017 Operating Results 112
  • 6.8 Aug 01, 2017: Proteome Sciences: Directorate changes 115
  • 6.9 Jul 25, 2017: Proteome Sciences: Interim Results for the Six Months Ended 30 June 2017 116
  • 6.10 Jul 25, 2017: NeoGenomics Reports Record Revenue of $66.1 Million on 16% Volume Growth and 13% Reduction in Average Cost per Test in the Second Quarter of 2017 117
  • 6.11 Jul 25, 2017: Cologuard revenue increased to $57.6 million during second quarter; Test volume grew 149 percent from second quarter of 2016 to 135,000 completed tests 118
  • 6.12 Jul 17, 2017: Leading expert on pancreatic cancer, Professor Stephen Pereira at University College London, joins Immunovia's Scientific Advisory Board 119
  • 6.13 Jul 17, 2017: Leading pancreatic cancer expert on early symptoms Professor Stephen Pereira at University College London joins Immunovia's Scientific Advisory Board 119
  • 6.14 Jun 28, 2017: Immunovia Establishes US Headquarters, Including CLIA Reference Laboratory, in Boston 120
  • 6.15 Jun 27, 2017: Avant Diagnostics Announces Confirmatory Clinical Utility Data for Theralink in Pancreatic Cancer 120
  • 6.16 Jun 13, 2017: Immunovia's biomarker signature for the diagnosis of pancreatic cancer now patented in Japan 121
  • 6.17 Jun 13, 2017: Immunovia´s biomarker signature for the diagnosis of pancreatic cancer now patented in Japan 121
  • 6.18 Jun 13, 2017: Cambridge Biomedical Names Linda Robbie, Ph.D., as VP of Scientific Affairs 122
  • 6.19 Jun 12, 2017: Proteome Sciences: New Registered Address 122
  • 6.20 Jun 08, 2017: Merrimack Announces Expansion of Senior Management Team with Appointment of Sergio Santillana as Chief Medical Officer and Ellen Forest as Head of Human Resources 122
  • 6.21 Jun 01, 2017: Helomics and the Pittsburgh Life Sciences Greenhouse Partner to Establish a Biotechnology Incubator Dedicated to Diagnostics and Precision Medicine 123
  • 6.22 May 25, 2017: Merrimack Announces Management Change 123
  • 6.23 May 15, 2017: ImmunoCellular Therapeutics Announces First Quarter 2017 Financial Results 124
  • 6.24 May 15, 2017: Interpace Diagnostics Group Reports First Quarter 2017 Financial Results, Business Progress and Recent Accomplishments 124
  • 6.25 May 11, 2017: VolitionRx Announces First Quarter 2017 Financial Results and Business Update 126
  • 6.26 May 10, 2017: Merrimack Reports First Quarter 2017 Financial Results 127
  • 6.27 May 10, 2017: Immunomedics Announces Third Quarter Fiscal 2017 Results And Clinical Program Developments 129
  • 6.28 May 09, 2017: OPKO Health Reports 2016 Financial and Operating Results 131
  • 6.29 May 09, 2017: Halozyme Reports First Quarter 2017 Financial Results 132
  • 6.30 May 05, 2017: Immunomedics Delivers Business Updates, Announces Private Placement Offering and Outlines Strategic Steps to Drive Stockholder Value 134
  • 6.31 May 03, 2017: Clovis Oncology Announces First Quarter 2017 Operating Results 136
  • 6.32 May 02, 2017: Myriad Genetics Reports Fiscal Third-Quarter 2017 Financial Results 139
  • 6.33 Apr 26, 2017: NeoGenomics Reports 15% Volume Growth and 10% Reduction in Average Cost per Test in the First Quarter of 2017 141
  • 6.34 Apr 20, 2017: Immunovia Interim report, January-March 2017 143
  • 6.35 Apr 20, 2017: NeoGenomics Appoints Bill Bonello as Vice President, Treasurer, and Director of Corporate Development 143
  • 6.36 Apr 19, 2017: New CEO Appointed From Within Sienna 144
  • 6.37 Apr 11, 2017: VolitionRx Appoints David Vanston as Chief Financial Officer 144
  • 6.38 Apr 05, 2017: SomaLogic announces the appointment of long-time Board member as Chief Executive Officer 145
  • 6.39 Apr 03, 2017: Proteome Sciences Announces Appointment of Richard Dennis as Chief Commercial Officer 145
  • 6.40 Mar 31, 2017: Edison Issues Update on Immunovia (IMMUNOV) 146
  • 6.41 Mar 29, 2017: Interpace Diagnostics Group Reports Fourth Quarter and Full Year 2016 Financial Results, Business Progress Against Plan and Recent Accomplishments 147
  • 6.42 Mar 28, 2017: Proteome Sciences Announces Preliminary results for the year ended 31 December 2016 Notice of AGM 149
  • 6.43 Mar 10, 2017: VolitionRx Announces Full Fiscal Year 2016 Financial Results and Business Update 158
  • 6.44 Mar 09, 2017: ImmunoCellular Therapeutics Announces Fourth Quarter and Full Year 2016 Financial Results and Provides Corporate Update 159
  • 6.45 Mar 06, 2017: Fluciclovine PET/CT improves radiotherapy targeting for recurrent prostate cancer 161
  • 6.46 Mar 03, 2017: OPKO Health Appoints Dr. Akhtar Ashfaq as Renal Division Senior Vice President, Clinical Research and Development 161
  • 6.47 Mar 01, 2017: OPKO Health Reports 2016 Financial and Operating Results 162
  • 6.48 Mar 01, 2017: Merrimack Reports Fourth Quarter and Full-Year 2016 Financial Results 163
  • 6.49 Feb 28, 2017: Halozyme Reports Fourth Quarter And Full Year 2016 Financial Results 165
  • 6.50 Feb 22, 2017: Clovis Oncology Announces 2016 Operating Results 166
  • 6.51 Feb 22, 2017: NeoGenomics Reports 122% Revenue Growth to $60.5 Million and 11% Reduction in Average Cost per Test in the Fourth Quarter of 2016 168
  • 6.52 Feb 15, 2017: Immunovia Financial Statement 2016 170
  • 6.53 Feb 09, 2017: Immunomedics Announces Second Quarter Fiscal 2017 Results and Clinical Program Developments 171
  • 6.54 Feb 07, 2017: Myriad Genetics Reports Fiscal Second-Quarter 2017 Financial Results 173
  • 6.55 Jan 18, 2017: Merrimack Names Richard Peters, M.D., Ph.D., as President and CEO 175
  • 6.56 Jan 16, 2017: Cancer Research Technology And Varleigh Dx (UK) Launch Test To Support Diagnosis Of Pancreatic Cancer 176
  • 6.57 Jan 16, 2017: University of Michigan Pancreatic Cancer Center new partner in Immunovia's global PANFAM-1 prospective validation study 176
  • 6.58 Jan 09, 2017: Immunomedics Announces Reconstituted Board of Directors and Leadership Succession Plan 177

7 Appendix 202

  • 7.1 Methodology 202
  • 7.2 About GlobalData 205
  • 7.3 Contact Us 205
  • 7.4 Disclaimer 205

List of Tables

1.1 List of Tables

  • Table 1: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 13
  • Table 2: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Territory 14
  • Table 3: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 15
  • Table 4: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 16
  • Table 5: Pancreatic Cancer Diagnostic Tests - Ongoing Clinical Trials 17
  • Table 6: Pancreatic Cancer Diagnostic Tests Companies - Pipeline Products by Stage of Development 18
  • Table 7: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 21
  • Table 8: A&G Pharmaceutical Inc Pipeline Products & Ongoing Clinical Trials Overview 24
  • Table 9: Companion Diagnostic Test - Pancreatic Cancer - Product Status 24
  • Table 10: Companion Diagnostic Test - Pancreatic Cancer - Product Description 24
  • Table 11: Abcodia Ltd Pipeline Products & Ongoing Clinical Trials Overview 25
  • Table 12: Diagnostic Assay - Pancreatic Cancer - Product Status 25
  • Table 13: Diagnostic Assay - Pancreatic Cancer - Product Description 25
  • Table 14: Acobiom Pipeline Products & Ongoing Clinical Trials Overview 26
  • Table 15: Companion Diagnostic Assay - Masitinib - Product Status 26
  • Table 16: Companion Diagnostic Assay - Masitinib - Product Description 26
  • Table 17: Diagnostic/Prognostic Assay - Pancreatic Cancer - Product Status 27
  • Table 18: Diagnostic/Prognostic Assay - Pancreatic Cancer - Product Description 27
  • Table 19: GemciTest - Product Status 27
  • Table 20: GemciTest - Product Description 28
  • Table 21: Advanced Marker Discovery SL Pipeline Products & Ongoing Clinical Trials Overview 29
  • Table 22: PancreaDix - Product Status 29
  • Table 23: PancreaDix - Product Description 29
  • Table 24: Andraka Technologies, LLC Pipeline Products & Ongoing Clinical Trials Overview 30
  • Table 25: Diagnostic Test - Pancreatic Cancer - Product Status 30
  • Table 26: Diagnostic Test - Pancreatic Cancer - Product Description 30
  • Table 27: Applied Proteomics Inc Pipeline Products & Ongoing Clinical Trials Overview 31
  • Table 28: API Diagnostic Test - Pancreatic Cancer - Product Status 31
  • Table 29: API Diagnostic Test - Pancreatic Cancer - Product Description 31
  • Table 30: Avant Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 32
  • Table 31: TheraLink Assay - Pancreatic Cancer - Product Status 32
  • Table 32: TheraLink Assay - Pancreatic Cancer - Product Description 32
  • Table 33: BioMarker Strategies LLC Pipeline Products & Ongoing Clinical Trials Overview 33
  • Table 34: Ex Vivo Biomarker Test - Pancreatic Cancer - Product Status 33
  • Table 35: Ex Vivo Biomarker Test - Pancreatic Cancer - Product Description 33
  • Table 36: Bioprognos SL Pipeline Products & Ongoing Clinical Trials Overview 34
  • Table 37: MBDAA Pancreatic Cancer Test - Product Status 34
  • Table 38: MBDAA Pancreatic Cancer Test - Product Description 34
  • Table 39: Biouniversa srl Pipeline Products & Ongoing Clinical Trials Overview 35
  • Table 40: BAG3 ELISA Kit - Pancreatic Adenocarcinoma - Product Status 35
  • Table 41: BAG3 ELISA Kit - Pancreatic Adenocarcinoma - Product Description 35
  • Table 42: BAG3 ELISA Kit - Pancreatic Adenocarcinoma Early Diagnosis - Product Status 36
  • Table 43: BAG3 ELISA Kit - Pancreatic Adenocarcinoma Early Diagnosis - Product Description 36
  • Table 44: Cancer Research Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 37
  • Table 45: IHC Based Test - Pancreatic Cancer - Product Status 37
  • Table 46: IHC Based Test - Pancreatic Cancer - Product Description 37
  • Table 47: Cepheid Pipeline Products & Ongoing Clinical Trials Overview 38
  • Table 48: XPERT Pancreatic CA Early Detection Test - Product Status 38
  • Table 49: XPERT Pancreatic CA Early Detection Test - Product Description 38
  • Table 50: Xpert Pancreatic CA Monitor Assay - Product Status 39
  • Table 51: Xpert Pancreatic CA Monitor Assay - Product Description 39
  • Table 52: Clovis Oncology Inc Pipeline Products & Ongoing Clinical Trials Overview 40
  • Table 53: hENT1 Companion Diagnostic Test - Product Status 40
  • Table 54: hENT1 Companion Diagnostic Test - Product Description 40
  • Table 55: CompanDX Ltd. Pipeline Products & Ongoing Clinical Trials Overview 41
  • Table 56: Biomarker Assay - Pancreatic Cancer - Product Status 41
  • Table 57: Biomarker Assay - Pancreatic Cancer - Product Description 41
  • Table 58: Courtagen Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 42
  • Table 59: Pancreatic Cancer Diagnostic Panel - Product Status 42
  • Table 60: Pancreatic Cancer Diagnostic Panel - Product Description 42
  • Table 61: CS-Keys, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 43
  • Table 62: caPCNA - Pancreatic Cancer - Product Status 43
  • Table 63: caPCNA - Pancreatic Cancer - Product Description 43
  • Table 64: Di.V.A.L Toscana srl Pipeline Products & Ongoing Clinical Trials Overview 44
  • Table 65: NanoMabKv - Pancreatic Cancer - Product Status 44
  • Table 66: NanoMabKv - Pancreatic Cancer - Product Description 44
  • Table 67: Exact Sciences Corp Pipeline Products & Ongoing Clinical Trials Overview 45
  • Table 68: Diagnostic Assay - Pancreatic Cancer - Product Status 45
  • Table 69: Diagnostic Assay - Pancreatic Cancer - Product Description 45
  • Table 70: Fred Hutchinson Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 46
  • Table 71: Diagnostic Test - Pancreatic Cancer - Product Status 46
  • Table 72: Diagnostic Test - Pancreatic Cancer - Product Description 46
  • Table 73: German Cancer Research Center Pipeline Products & Ongoing Clinical Trials Overview 47
  • Table 74: Diagnostic Assay - Pancreatic Cancer - Product Status 47
  • Table 75: Diagnostic Assay - Pancreatic Cancer - Product Description 47
  • Table 76: GlycoZym Pipeline Products & Ongoing Clinical Trials Overview 48
  • Table 77: Diagnostic Assay - Pancreatic Cancer - Product Status 48
  • Table 78: Diagnostic Assay - Pancreatic Cancer - Product Description 48
  • Table 79: Health Discovery Corp Pipeline Products & Ongoing Clinical Trials Overview 49
  • Table 80: Diagnostic Test - Pancreatic Cancer - Product Status 49
  • Table 81: Diagnostic Test - Pancreatic Cancer - Product Description 49
  • Table 82: Hebrew University of Jerusalem Pipeline Products & Ongoing Clinical Trials Overview 50
  • Table 83: Diagnostic Assay - Pancreatic Cancer - Product Status 50
  • Table 84: Diagnostic Assay - Pancreatic Cancer - Product Description 50
  • Table 85: ImmunoCellular Therapeutics Ltd Pipeline Products & Ongoing Clinical Trials Overview 51
  • Table 86: Diagnostic Test - Pancreatic Cancer - Product Status 51
  • Table 87: Diagnostic Test - Pancreatic Cancer - Product Description 51
  • Table 88: Immunomedics Inc Pipeline Products & Ongoing Clinical Trials Overview 52
  • Table 89: Companion Diagnostic Assay - Clivatuzumab - Product Status 52
  • Table 90: Companion Diagnostic Assay - Clivatuzumab - Product Description 52
  • Table 91: Immunovia AB Pipeline Products & Ongoing Clinical Trials Overview 53
  • Table 92: IMMray PanCan-d - Product Status 53
  • Table 93: IMMray PanCan-d - Product Description 53
  • Table 94: IMMray PanCan-m Test - Product Status 54
  • Table 95: IMMray PanCan-m Test - Product Description 54
  • Table 96: Immunovia AB - Ongoing Clinical Trials Overview 55
  • Table 97: IMMray PanCan-d - Validation of Early Detection Blood Test for Pancreatic Cancer 56
  • Table 98: Imperial College London Pipeline Products & Ongoing Clinical Trials Overview 57
  • Table 99: Prognostic Assay - Pancreatic Cancer - Product Status 57
  • Table 100: Prognostic Assay - Pancreatic Cancer - Product Description 57
  • Table 101: IV Diagnostics, Inc. Pipeline Products & Ongoing Clinical Trials Overview 58
  • Table 102: Diagnostic Test - Pancreatic Cancer - Product Status 58
  • Table 103: Diagnostic Test - Pancreatic Cancer - Product Description 58
  • Table 104: John Hopkins University Pipeline Products & Ongoing Clinical Trials Overview 59
  • Table 105: Protein Biomarker Assay - Pancreatic Cancer - Product Status 59
  • Table 106: Protein Biomarker Assay - Pancreatic Cancer - Product Description 59
  • Table 107: Leitat Technological Center Pipeline Products & Ongoing Clinical Trials Overview 60
  • Table 108: ELISA Kit - S100A4 - Pancreatic Cancer - Product Status 60
  • Table 109: ELISA Kit - S100A4 - Pancreatic Cancer - Product Description 60
  • Table 110: ELISA Kit - S100P - Pancreatic Cancer - Product Status 61
  • Table 111: ELISA Kit - S100P - Pancreatic Cancer - Product Description 61
  • Table 112: Luminor Medical Technologies Inc Pipeline Products & Ongoing Clinical Trials Overview 62
  • Table 113: Diagnostic Test - Pancreatic Cancer - Product Status 62
  • Table 114: Diagnostic Test - Pancreatic Cancer - Product Description 62
  • Table 115: Matrix-Bio, Inc. Pipeline Products & Ongoing Clinical Trials Overview 63
  • Table 116: VeraMarker Pancreatic Cancer Test - Product Status 63
  • Table 117: VeraMarker Pancreatic Cancer Test - Product Description 63
  • Table 118: Mayo Clinic US Pipeline Products & Ongoing Clinical Trials Overview 64
  • Table 119: Methylation Biomarker Test - Pancreatic Cancer - Product Status 64
  • Table 120: Methylation Biomarker Test - Pancreatic Cancer - Product Description 64
  • Table 121: MDNA Life Sciences Inc Pipeline Products & Ongoing Clinical Trials Overview 65
  • Table 122: Diagnostic Assay - Pancreatic Cancer - Product Status 65
  • Table 123: Diagnostic Assay - Pancreatic Cancer - Product Description 65
  • Table 124: Merrimack Pharmaceuticals Inc Pipeline Products & Ongoing Clinical Trials Overview 66
  • Table 125: MM-141 Companion Diagnostic Assay - Pancreatic Cancer - Product Status 66
  • Table 126: MM-141 Companion Diagnostic Assay - Pancreatic Cancer - Product Description 66
  • Table 127: Metanomics Health GmbH Pipeline Products & Ongoing Clinical Trials Overview 67
  • Table 128: Diagnostic Assay - Pancreatic Cancer - Product Status 67
  • Table 129: Diagnostic Assay - Pancreatic Cancer - Product Description 67
  • Table 130: Milagen Inc Pipeline Products & Ongoing Clinical Trials Overview 68
  • Table 131: Immunoassay - Pancreatic Cancer - Product Status 68
  • Table 132: Immunoassay - Pancreatic Cancer - Product Description 68
  • Table 133: Myriad Genetics Inc Pipeline Products & Ongoing Clinical Trials Overview 69
  • Table 134: myPath Pancreatic Cancer - Product Status 69
  • Table 135: myPath Pancreatic Cancer - Product Description 69
  • Table 136: Nanocytomics LLC Pipeline Products & Ongoing Clinical Trials Overview 70
  • Table 137: Screening Test - Pancreatic Cancer - Product Status 70
  • Table 138: Screening Test - Pancreatic Cancer - Product Description 70
  • Table 139: NanoScale Corporation Pipeline Products & Ongoing Clinical Trials Overview 71
  • Table 140: Diagnostic Test - Pancreatic Cancer - Product Status 71
  • Table 141: Diagnostic Test - Pancreatic Cancer - Product Description 71
  • Table 142: NatiMab Therapeutics Srl Pipeline Products & Ongoing Clinical Trials Overview 72
  • Table 143: Diagnostic Test - Pancreas Adenocarcinoma - Product Status 72
  • Table 144: Diagnostic Test - Pancreas Adenocarcinoma - Product Description 72
  • Table 145: National Cheng-Kung University Hospital Pipeline Products & Ongoing Clinical Trials Overview 73
  • Table 146: Diagnostic Biomarker - Pancreatic Cancer - Product Status 73
  • Table 147: Diagnostic Biomarker - Pancreatic Cancer - Product Description 73
  • Table 148: Oncomatryx Biopharma SL Pipeline Products & Ongoing Clinical Trials Overview 74
  • Table 149: ELISA-Based Companion Diagnostic Kit - MTX3 - Product Status 74
  • Table 150: ELISA-Based Companion Diagnostic Kit - MTX3 - Product Description 74
  • Table 151: Immunohistochemistry Based Companion Diagnostic Kit - MTX3 - Product Status 75
  • Table 152: Immunohistochemistry Based Companion Diagnostic Kit - MTX3 - Product Description 75
  • Table 153: Onconome, Inc. (Inactive) Pipeline Products & Ongoing Clinical Trials Overview 76
  • Table 154: Pan Cancer Screening and Detection Test - Product Status 76
  • Table 155: Pan Cancer Screening and Detection Test - Product Description 76
  • Table 156: Pan-Cancer Metastatic Marker Test - Product Status 77
  • Table 157: Pan-Cancer Metastatic Marker Test - Product Description 77
  • Table 158: OPKO Health Inc Pipeline Products & Ongoing Clinical Trials Overview 78
  • Table 159: Diagnostic Test - Pancreatic Cancer - Product Status 78
  • Table 160: Diagnostic Test - Pancreatic Cancer - Product Description 78
  • Table 161: Oxford Gene Technology Ltd Pipeline Products & Ongoing Clinical Trials Overview 79
  • Table 162: Diagnostic Test - Pancreatic Cancer - Product Status 79
  • Table 163: Diagnostic Test - Pancreatic Cancer - Product Description 79
  • Table 164: PeriRx LLC Pipeline Products & Ongoing Clinical Trials Overview 80
  • Table 165: Saliva Test - Pancreatic Cancer - Product Status 80
  • Table 166: Saliva Test - Pancreatic Cancer - Product Description 80
  • Table 167: Precision Biologics Inc Pipeline Products & Ongoing Clinical Trials Overview 81
  • Table 168: Diagnostic Assay - Pancreatic Cancer - Product Status 81
  • Table 169: Diagnostic Assay - Pancreatic Cancer - Product Description 81
  • Table 170: NEO-301 IHC Test - Product Status 82
  • Table 171: NEO-301 IHC Test - Product Description 82
  • Table 172: Proplex Technologies Llc Pipeline Products & Ongoing Clinical Trials Overview 83
  • Table 173: Biomarker Diagnostic Test - Pancreatic Cancer - Product Status 83
  • Table 174: Biomarker Diagnostic Test - Pancreatic Cancer - Product Description 83
  • Table 175: Protagen AG Pipeline Products & Ongoing Clinical Trials Overview 84
  • Table 176: Diagnostic Assay - Pancreatic Cancer - Product Status 84
  • Table 177: Diagnostic Assay - Pancreatic Cancer - Product Description 84
  • Table 178: Proteome Sciences Plc Pipeline Products & Ongoing Clinical Trials Overview 85
  • Table 179: SysQuant Global Phosphorylation Assay - Biopsy Tissue - Product Status 85
  • Table 180: SysQuant Global Phosphorylation Assay - Biopsy Tissue - Product Description 85
  • Table 181: Queen Mary University of London Pipeline Products & Ongoing Clinical Trials Overview 86
  • Table 182: Biomarker Assay - Pancreatic Ductal Adenocarcinoma - Product Status 86
  • Table 183: Biomarker Assay - Pancreatic Ductal Adenocarcinoma - Product Description 86
  • Table 184: Rutgers The State University of New Jersey Pipeline Products & Ongoing Clinical Trials Overview 87
  • Table 185: Blood Test - Pancreatic Cancer - Product Status 87
  • Table 186: Blood Test - Pancreatic Cancer - Product Description 87
  • Table 187: SDIX LLC Pipeline Products & Ongoing Clinical Trials Overview 88
  • Table 188: Pancreatic Cancer Assay - Product Status 88
  • Table 189: Pancreatic Cancer Assay - Product Description 88
  • Table 190: Sienna Cancer Diagnostics Ltd Pipeline Products & Ongoing Clinical Trials Overview 89
  • Table 191: Sienna Test - Pancreatic Cancer - Product Status 89
  • Table 192: Sienna Test - Pancreatic Cancer - Product Description 89
  • Table 193: SomaLogic Inc Pipeline Products & Ongoing Clinical Trials Overview 90
  • Table 194: SOMAscan Assay - Pancreatic Cancer - Product Status 90
  • Table 195: SOMAscan Assay - Pancreatic Cancer - Product Description 90
  • Table 196: Stanford University Pipeline Products & Ongoing Clinical Trials Overview 91
  • Table 197: Biomarker Assay - Pancreatic Cyst - Product Status 91
  • Table 198: Biomarker Assay - Pancreatic Cyst - Product Description 91
  • Table 199: Temple University Health System Pipeline Products & Ongoing Clinical Trials Overview 92
  • Table 200: Diagnostic Test - Pancreatic Cancer - Product Status 92
  • Table 201: Diagnostic Test - Pancreatic Cancer - Product Description 92
  • Table 202: The Royal Marsden NHS Foundation Trust Pipeline Products & Ongoing Clinical Trials Overview 93
  • Table 203: Pancreatic Cancer Blood Test - Product Status 93
  • Table 204: Pancreatic Cancer Blood Test - Product Description 93
  • Table 205: The University of North Carolina at Chapel Hill Pipeline Products & Ongoing Clinical Trials Overview 94
  • Table 206: Biomarker Assay - Pancreatic Cancer - Product Status 94
  • Table 207: Biomarker Assay - Pancreatic Cancer - Product Description 94
  • Table 208: Thomas Jefferson University Pipeline Products & Ongoing Clinical Trials Overview 95
  • Table 209: Diagnostic Test - Pancreatic Cancer - Product Status 95
  • Table 210: Diagnostic Test - Pancreatic Cancer - Product Description 95
  • Table 211: University of Illinois at Chicago Pipeline Products & Ongoing Clinical Trials Overview 96
  • Table 212: Diagnostic Test - Pancreatic Cancer - Product Status 96
  • Table 213: Diagnostic Test - Pancreatic Cancer - Product Description 96
  • Table 214: University of Pennsylvania Pipeline Products & Ongoing Clinical Trials Overview 97
  • Table 215: Liquid Biopsy Test - Pancreatic Cancer - Product Status 97
  • Table 216: Liquid Biopsy Test - Pancreatic Cancer - Product Description 97
  • Table 217: University of Texas MD Anderson Cancer Center Pipeline Products & Ongoing Clinical Trials Overview 98
  • Table 218: Biomarker Test - Pancreatic Cancer - Product Status 98
  • Table 219: Biomarker Test - Pancreatic Cancer - Product Description 98
  • Table 220: US Biomarkers Inc Pipeline Products & Ongoing Clinical Trials Overview 99
  • Table 221: Blood-Based Biomarker - Pancreatic Cancer - Product Status 99
  • Table 222: Blood-Based Biomarker - Pancreatic Cancer - Product Description 99
  • Table 223: Ventana Medical Systems Inc Pipeline Products & Ongoing Clinical Trials Overview 100
  • Table 224: PEGPH20 Companion Diagnostic Assay - Pancreatic Cancer - Product Status 100
  • Table 225: PEGPH20 Companion Diagnostic Assay - Pancreatic Cancer - Product Description 100
  • Table 226: Viomics Inc. Pipeline Products & Ongoing Clinical Trials Overview 101
  • Table 227: Viomics Diagnostic Assay - Pancreatic Cancer - Product Status 101
  • Table 228: Viomics Diagnostic Assay - Pancreatic Cancer - Product Description 101
  • Table 229: Vitatex Inc. Pipeline Products & Ongoing Clinical Trials Overview 102
  • Table 230: Pancreatic Cancer CTC Detection Kit - Product Status 102
  • Table 231: Pancreatic Cancer CTC Detection Kit - Product Description 102
  • Table 232: VolitionRX Ltd Pipeline Products & Ongoing Clinical Trials Overview 103
  • Table 233: NuQ Diagnostic Test - Pancreatic Cancer - Product Status 103
  • Table 234: NuQ Diagnostic Test - Pancreatic Cancer - Product Description 103
  • Table 235: VolitionRX Ltd - Ongoing Clinical Trials Overview 104
  • Table 236: NuQ Diagnostic Test - Pancreatic Cancer - Clinical Trial with German Cancer Research Center (DKFZ) to Evaluate NuQ Blood Test for Pancreatic Cancer 105
  • Table 237: Glossary 204

List of Figures

1.2 List of Figures

  • Figure 1: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Stage of Development 13
  • Figure 2: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Territory 14
  • Figure 3: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Regulatory Path 15
  • Figure 4: Pancreatic Cancer Diagnostic Tests - Pipeline Products by Estimated Approval Date 16
  • Figure 5: Pancreatic Cancer Diagnostic Tests - Ongoing Clinical Trials 17
Back to Top